KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) EBT: 2017-2024

Historic EBT for Aquestive Therapeutics (AQST) over the last 8 years, with Dec 2024 value amounting to -$44.2 million.

  • Aquestive Therapeutics' EBT fell 34.21% to -$15.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$69.0 million, marking a year-over-year decrease of 96.61%. This contributed to the annual value of -$44.2 million for FY2024, which is 479.03% down from last year.
  • Per Aquestive Therapeutics' latest filing, its EBT stood at -$44.2 million for FY2024, which was down 479.03% from -$7.6 million recorded in FY2023.
  • Over the past 5 years, Aquestive Therapeutics' EBT peaked at -$7.6 million during FY2023, and registered a low of -$70.5 million during FY2021.
  • Over the past 3 years, Aquestive Therapeutics' median EBT value was -$44.2 million (recorded in 2024), while the average stood at -$35.4 million.
  • Its EBT has fluctuated over the past 5 years, first skyrocketed by 85.99% in 2023, then tumbled by 479.03% in 2024.
  • Over the past 5 years, Aquestive Therapeutics' EBT (Yearly) stood at -$55.8 million in 2020, then dropped by 26.45% to -$70.5 million in 2021, then rose by 22.87% to -$54.4 million in 2022, then soared by 85.99% to -$7.6 million in 2023, then crashed by 479.03% to -$44.2 million in 2024.